In the top alliance by deal value, PTC Therapeutics granted Novartis Pharmaceuticals exclusive global rights to its PTC518 Huntington’s disease program, which includes related molecules.
Under the agreement, PTC will receive an up-front payment of $1bn, up to $1
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?